Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Springworks Therapeutics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 distinct examiners and 4 distinct art units. Each matter has a separate examiner, while one art unit handles more than one listed matter. This creates examiner-level diversity with some unit-level continuity.
SIMMONS, CHRIS E is the busiest examiner, with 1 pending matter. No examiner has a concentrated share of the docket. Counsel should coordinate common scientific positions centrally while adapting claim amendments and interview preparation to the individual examiner assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIMMONS, CHRIS E | 1 | 34.2% | +19.6% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19237417 | IMPROVED MIRDAMETINIB TREATMENT | SIMMONS, CHRIS E | 44d overdue |
| 18908159 | TREATMENTS WITH NIROGACESTAT | DAVIS, BRIAN J | — |
| 18694483 | METHODS OF TREATING MULTIPLE MYELOMA | DENT, ALANA HARRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19237417 | IMPROVED MIRDAMETINIB TREATMENT | SIMMONS, CHRIS E | 44d overdue |
| 18841882 | Treatment of cutaneous neurofibromas with Mirdametinib | RAMACHANDRAN, UMAMAHESWARI | — |
| 18694483 | METHODS OF TREATING MULTIPLE MYELOMA | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1614 | 1 |
| 1627 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19237417 | IMPROVED MIRDAMETINIB TREATMENT | SIMMONS, CHRIS E | 1622 | §102§103§112Other | Non-Final OA | 44d overdue | Pending | Jun 13, 2025 |
| 18908159 | TREATMENTS WITH NIROGACESTAT | DAVIS, BRIAN J | 1614 | §103§112Other | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18841882 | Treatment of cutaneous neurofibromas with Mirdametinib | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18694483 | METHODS OF TREATING MULTIPLE MYELOMA | DENT, ALANA HARRIS | 1643 | §102§103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpringworks Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Chris E Simmons has the most, with 1 of Springworks Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
